Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | VDR | P11473 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12267208 | 0.92 | HTT (0.57) | ARHTTHIF1AKMT2AKDM4E | |
| SCHEMBL12267202 | 0.90 | AR (0.74) | ARHTTHIF1AKMT2AKDM4E | |
| SCHEMBL19677336 | 0.90 | AR (0.74) | ARHTTHIF1AKMT2AKDM4E | |
| SCHEMBL12267331 | 0.90 | AR (0.74) | ARHTTHIF1AKMT2AKDM4E | |
| SCHEMBL868711 | 0.88 | AR (0.85) | ARHTTHIF1AKMT2AKDM4E | |
| SCHEMBL12363856 | 0.88 | AR (0.85) | ARHTTHIF1AKMT2AKDM4E | |
| SCHEMBL12570312 | 0.87 | AR (0.82) | ARHTTHIF1AKMT2AKDM4E | |
| SCHEMBL13826212 | 0.86 | AR (0.82) | ARHTTHIF1AKMT2AKDM4E | |
| SCHEMBL12267221 | 0.86 | AR (0.82) | ARHTTHIF1AKMT2AKDM4E | |
| SCHEMBL14707520 | 0.86 | AR (0.82) | ARHTTHIF1AKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862667-B2 | Diglycidic ether derivative therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-01-09 | — | — | US | disclosed |
| US-20170121261-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNITED STATES GOVERNMENT | 2017-05-04 | — | — | US | disclosed |
| US-20130245129-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-09-19 | — | — | US | disclosed |
| US-20110230556-A1 | Diglycidic Ether Derivative Therapeutics and Methods for Their Use | THE UNITED STATES GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121261-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | UGCG, PTGFR, KLK3 | AR 206/4885HTT 4813/4885HIF1A 530/4885 |
| US-20130245129-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | MAN2B2, UGCG, KLK3 | AR 179/4885HTT 4659/4885HIF1A 1235/4885 |
| US-20110230556-A1 | Diglycidic Ether Derivative Therapeutics and Methods for Their Use | MAN2B2, KLK3, UGCG | AR 125/4885HTT 4653/4885HIF1A 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.